Conditions: nausea · semaglutide · SUSTAIN-6.
I would like to know the limits of what can be inferred from this.
What I am trying to avoid is over-reading a single result, which I have done before.
How should I read this, and where are the traps?
Take it from the SUSTAIN-6 adverse-event table by arm, and check the unit before you use it. An incidence can be the proportion of participants who reported the event at least once, or the count of events divided by exposure time, and the two differ by however many people had it repeatedly. Then subtract the placebo arm, because the untreated rate is not zero. And read the discontinuation column beside it: an event that made people leave the trial is under-counted at every later visit, so a low late-timepoint incidence can mean the event was severe rather than rare.
Start with the timing relative to the last dose increase, because escalation-related nausea and steady-state nausea have different explanations and different responses.
The area postrema lies outside the blood-brain barrier and expresses GLP-1 receptors densely. That is why a large peptide can trigger nausea centrally at all, and why the effect tracks exposure rather than gastric contents.
It helps to be literal here: tolerance develops through receptor desensitisation over one to two weeks at a stable dose. Escalating before that has happened resets the process, which is the mechanism behind most miserable titrations.
Area postrema involvement in nausea from GLP-1 receptor agonism is supported by lesion studies in animals and by the anatomy of the circumventricular organs.
Smaller meals, less fat, stop at first fullness, fluids between meals.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsThis is the most common adverse effect in the class and the one with the most consistent management advice.
Extending the interval before the next escalation is the intervention with the best evidence. Trials titrated at four-week intervals for exactly this reason.
In practice, alcohol is poorly tolerated in this context for two reasons — delayed emptying alters absorption kinetics, and it irritates a stomach already under strain.
Persistent vomiting is a clinical matter, not a tolerance matter.
edited 28 Oct 2024 by Dr_Lena_Ostrowska — fixed an arithmetic slip in the third paragraph
Answering this needs to know the titration schedule, since going up faster than the label schedule is the commonest reason for a bad time.
Nausea persisting for more than a few weeks at a stable dose, or accompanied by severe abdominal pain, is outside the ordinary pattern and needs assessment rather than management.
Specifically, trial incidence for nausea in this class runs to roughly a quarter to a half of participants depending on agent and dose, concentrated in the escalation phase, with discontinuation for it in low single-figure percentages.
Hold the dose rather than escalating. Tolerance needs one to two weeks to develop.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.